Zhiwei Hu

Education:

M. D.	Medicine and Stomatology, Jiangxi Medical College, China, 1991
M. S.	Tumor Immunology, Jiangxi Medical College, China, 1994
Ph. D.	Tumor Immunobiology, Hunan Medical University, China, 1997

Highlight Of Qualifications

• 20-year experiences in tumor immunology, oncology and cancer immunotherapy and diagnosis using monoclonal antibody, phage display antibody and recombinant factor VII/IgG1 Fc (Icon) immunoconjugates
• 15-year experiences in molecular biology, adenoviral gene therapy for cancer and 10-year experiences in targeted photodynamic therapy for cancer and macular degeneration
• Principal Investigator and Research Associate Professor (Research Scientist) of a research laboratory at Yale School of Medicine during 2002-2012
• Recipient and Principal Investigator of four independent research grants from Komen For the Cure Foundation, Connecticut State Department of Public Health, Breast Cancer Alliance and Swebilius Foundation/Yale Cancer Center
• 7-year experiences as Scientific Advisor for Iconic Therapeutics, a Yale startup biotech company
• Co-inventor of 5 US Patents and 4 international patents of neovascular-targeted immunoconjugates (ICON) and their uses (for treatment of cancer, macular degeneration, rheumatoid arthritis, atherosclerosis, etc)
• Serving as the Editor-in-Chief of Open Journal of Immunology, Co-Editor-in-Chief of the Journal of Analytical & Bioanalytical Techniques, an editorial board member of numerous peer-reviewed journals in immunology and cancer research and as peer reviewer for peer-reviewed journals in immunology, photomedicine and cancer research
• Served as Co-Principal Investigator on an Investigator IND for Phase I clinical trial of the use of replication-deficient adenoviral vector encoding a novel immunoconjugate (Icon) composed of coagulation active site-mutated factor VII fused to the constant domain of immunoglobulin G (IgG Fc) for immunotherapy of patients with melanoma
• Extensive experience with primary immune cells of human and rodent origins, in vitro and in vivo preclinical studies on efficacy and safety of translational cancer research
• Excellent communication skills, both verbal and written, and strong interpersonal skills and presentation skills as well as a robust publication record in peer-reviewed journals
• Innovative, strong logical and analytical thinking skills and experiences in discovery and development of targeted cancer therapies
• A team player